197 related articles for article (PubMed ID: 26183543)
1. Discovery of potent and selective nonplanar tankyrase inhibiting nicotinamide mimics.
Nkizinkiko Y; Suneel Kumar BVS; Jeankumar VU; Haikarainen T; Koivunen J; Madhuri C; Yogeeswari P; Venkannagari H; Obaji E; Pihlajaniemi T; Sriram D; Lehtiö L
Bioorg Med Chem; 2015 Aug; 23(15):4139-4149. PubMed ID: 26183543
[TBL] [Abstract][Full Text] [Related]
2. Tankyrases as drug targets.
Lehtiö L; Chi NW; Krauss S
FEBS J; 2013 Aug; 280(15):3576-93. PubMed ID: 23648170
[TBL] [Abstract][Full Text] [Related]
3. para-Substituted 2-phenyl-3,4-dihydroquinazolin-4-ones as potent and selective tankyrase inhibitors.
Haikarainen T; Koivunen J; Narwal M; Venkannagari H; Obaji E; Joensuu P; Pihlajaniemi T; Lehtiö L
ChemMedChem; 2013 Dec; 8(12):1978-85. PubMed ID: 24130191
[TBL] [Abstract][Full Text] [Related]
4. Discovery of tankyrase inhibiting flavones with increased potency and isoenzyme selectivity.
Narwal M; Koivunen J; Haikarainen T; Obaji E; Legala OE; Venkannagari H; Joensuu P; Pihlajaniemi T; Lehtiö L
J Med Chem; 2013 Oct; 56(20):7880-9. PubMed ID: 24116873
[TBL] [Abstract][Full Text] [Related]
5. Screening and structural analysis of flavones inhibiting tankyrases.
Narwal M; Haikarainen T; Fallarero A; Vuorela PM; Lehtiö L
J Med Chem; 2013 May; 56(9):3507-17. PubMed ID: 23574272
[TBL] [Abstract][Full Text] [Related]
6. Structural basis of selective inhibition of human tankyrases.
Narwal M; Venkannagari H; Lehtiö L
J Med Chem; 2012 Feb; 55(3):1360-7. PubMed ID: 22233320
[TBL] [Abstract][Full Text] [Related]
7. Discovery and Optimization of 2-Arylquinazolin-4-ones into a Potent and Selective Tankyrase Inhibitor Modulating Wnt Pathway Activity.
Buchstaller HP; Anlauf U; Dorsch D; Kuhn D; Lehmann M; Leuthner B; Musil D; Radtki D; Ritzert C; Rohdich F; Schneider R; Esdar C
J Med Chem; 2019 Sep; 62(17):7897-7909. PubMed ID: 31381853
[TBL] [Abstract][Full Text] [Related]
8. Zoning in on Tankyrases: A Brief Review on the Past, Present and Prospective Studies.
Peters XQ; Malinga TH; Agoni C; Olotu FA; Soliman MES
Anticancer Agents Med Chem; 2019; 19(16):1920-1934. PubMed ID: 31648650
[TBL] [Abstract][Full Text] [Related]
9. Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors.
Hua Z; Bregman H; Buchanan JL; Chakka N; Guzman-Perez A; Gunaydin H; Huang X; Gu Y; Berry V; Liu J; Teffera Y; Huang L; Egge B; Emkey R; Mullady EL; Schneider S; Andrews PS; Acquaviva L; Dovey J; Mishra A; Newcomb J; Saffran D; Serafino R; Strathdee CA; Turci SM; Stanton M; Wilson C; Dimauro EF
J Med Chem; 2013 Dec; 56(24):10003-15. PubMed ID: 24294969
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships of 2-arylquinazolin-4-ones as highly selective and potent inhibitors of the tankyrases.
Nathubhai A; Haikarainen T; Hayward PC; Muñoz-Descalzo S; Thompson AS; Lloyd MD; Lehtiö L; Threadgill MD
Eur J Med Chem; 2016 Aug; 118():316-27. PubMed ID: 27163581
[TBL] [Abstract][Full Text] [Related]
11. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
12. 2-Phenylquinazolinones as dual-activity tankyrase-kinase inhibitors.
Nkizinkiko Y; Desantis J; Koivunen J; Haikarainen T; Murthy S; Sancineto L; Massari S; Ianni F; Obaji E; Loza MI; Pihlajaniemi T; Brea J; Tabarrini O; Lehtiö L
Sci Rep; 2018 Jan; 8(1):1680. PubMed ID: 29374194
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a Novel Series of Tankyrase Inhibitors by a Hybridization Approach.
Anumala UR; Waaler J; Nkizinkiko Y; Ignatev A; Lazarow K; Lindemann P; Olsen PA; Murthy S; Obaji E; Majouga AG; Leonov S; von Kries JP; Lehtiö L; Krauss S; Nazaré M
J Med Chem; 2017 Dec; 60(24):10013-10025. PubMed ID: 29155568
[TBL] [Abstract][Full Text] [Related]
14. Novel binding mode of a potent and selective tankyrase inhibitor.
Gunaydin H; Gu Y; Huang X
PLoS One; 2012; 7(3):e33740. PubMed ID: 22438990
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket.
Bregman H; Gunaydin H; Gu Y; Schneider S; Wilson C; DiMauro EF; Huang X
J Med Chem; 2013 Feb; 56(3):1341-5. PubMed ID: 23316926
[TBL] [Abstract][Full Text] [Related]
16. Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2.
Qiu W; Lam R; Voytyuk O; Romanov V; Gordon R; Gebremeskel S; Vodsedalek J; Thompson C; Beletskaya I; Battaile KP; Pai EF; Rottapel R; Chirgadze NY
Acta Crystallogr D Biol Crystallogr; 2014 Oct; 70(Pt 10):2740-53. PubMed ID: 25286857
[TBL] [Abstract][Full Text] [Related]
17. Insights of tankyrases: A novel target for drug discovery.
Damale MG; Pathan SK; Shinde DB; Patil RH; Arote RB; Sangshetti JN
Eur J Med Chem; 2020 Dec; 207():112712. PubMed ID: 32877803
[TBL] [Abstract][Full Text] [Related]
18. Tankyrase inhibitors as therapeutic targets for cancer.
Kamal A; Riyaz S; Srivastava AK; Rahim A
Curr Top Med Chem; 2014; 14(17):1967-76. PubMed ID: 25262803
[TBL] [Abstract][Full Text] [Related]
19. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
Mariotti L; Pollock K; Guettler S
Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
[TBL] [Abstract][Full Text] [Related]
20. Structure-based design, synthesis and evaluation in vitro of arylnaphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases.
Kumpan K; Nathubhai A; Zhang C; Wood PJ; Lloyd MD; Thompson AS; Haikarainen T; Lehtiö L; Threadgill MD
Bioorg Med Chem; 2015 Jul; 23(13):3013-32. PubMed ID: 26026769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
